/   Home   /   Newsroom   /   Research News

Hsp90 Inhibition Destabilizes Ezh2 Protein in Alloreactive T cells and Reduces GVHD

Jun 03, 2017     Email"> PrintText Size

Graft-versus-host disease (GVHD) remains the major cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation (allo-HSCT). It involves complex interactions of immune cells, induction of host-reactive donor effector T cells, and donor T cell-mediated injury to normal tissues. Epigenetic changes have been implicated in T cell-mediated GVHD.

Ezh2 is a histone methyltransferase specifically catalyzing the trimethylation of histone 3 at lysine 27. Genetic ablation of Ezh2 in T cells has been shown to reduce alloreactive T cell responses and the subsequent development of GVHD.

Researchers from Dr. ZHANG Yanyun’s lab at Shanghai Institutes for Biological Sciences of Chinese Academy of Sciences revealed for the first time that Ezh2 promotes the alloreactive T cell-mediated GVHD in a H3K27me3-independent mechanism.

Inhibiting Hsp90 by its specific inhibitor AUY922 destabilized Ezh2 protein and reduced alloreactive T cell-mediated GVHD, but preserved T cell ability against leukemia, leading to markedly improved survival of mice after allo-HSCT. The recent Blood journal has published the study, and this paper has been recommended as a cover art paper.

To test the translational potential of pharmacological Ezh2 inhibition in GVHD therapy, researchers found that simply reducing the level of H3K27me3 by administration of the Ezh2 inhibitor GSK126, UNC1999 or EPZ6438, could not prevent GVHD. In contrast, inhibiting Hsp90 by its specific inhibitor AUY922 destabilized Ezh2 protein in T cells, reduced GVHD, and preserved T cell mediated anti-leukemia activity.

This effect was accompanied by significantly decreased survival and expansion of alloreactive T cells that produced high levels of IFN-γ and TNF-α in vivo.

Introduction of Ezh2 in alloreactive T cells restored their expansion and production of effector cytokines upon AUY922 treatment, suggesting that the impaired T cell alloreactivity by inhibiting Hsp90 is achieved mainly through reducing the protein level of Ezh2.

The findings identified a previously unrecognized molecular mechanism by which Ezh2 and Hsp90 are integrated to regulate alloreactive T cell responses and GVHD. Targeting the Ezh2-Hsp90 complex using AUY922 represents a novel and clinically relevant approach to reduce GVHD while preserving GVL effects, thereby improving the efficacy of allo-HSCT.

This work was supported by National Natural Science Foundation of China, the Ministry of Science and Technology of China, Strategic Priority Research Program of the Chinese Academy of Sciences, and the Program of Science and Technology Commission of Shanghai Municipality, China.


(Editor: LIU Jia)

Related Articles

T cell;integrin b7 deficiency;immunity

Integrin β7 Required for Controlling Innate Immune-mediated Colitis

Aug 04, 2015

Dr. ZHANG Hailong and ZHENG Yajuan led by Professor CHEN Jianfeng from the Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences demonstrate that integrin β7

CD8+;T cell;Antitumor Immunity

Enzyme ‘Holds Key to Cancer’

Mar 18, 2016

Scientists found that inhibiting cholesterol esterification can potentiate the antitumor activity of CD8+ T cells (also known as killer T cells). This new way of improving T cell function might be used as a complement to current cancer immunotherapies, such as immune che...

Contact Us

Copyright © 2002 - Chinese Academy of Sciences